Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions

被引:17
|
作者
Sugaya, Nobuyoshi [1 ]
Furuya, Toshio [1 ]
机构
[1] PharmaDesign Inc, Div Res & Dev, Drug Discovery Dept, Chuo Ku, Tokyo, Japan
来源
BMC BIOINFORMATICS | 2011年 / 12卷
关键词
INTERACTION INHIBITORS; INTERACTION NETWORK; SMALL MOLECULES; TARGET; CLASSIFICATION; KNOWLEDGEBASE; RECOGNITION; INFORMATION; INTERFACES; DISCOVERY;
D O I
10.1186/1471-2105-12-50
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: The amount of data on protein-protein interactions (PPIs) available in public databases and in the literature has rapidly expanded in recent years. PPI data can provide useful information for researchers in pharmacology and medicine as well as those in interactome studies. There is urgent need for a novel methodology or software allowing the efficient utilization of PPI data in pharmacology and medicine. Results: To address this need, we have developed the 'Druggable Protein-protein Interaction Assessment System' (Dr. PIAS). Dr. PIAS has a meta-database that stores various types of information (tertiary structures, drugs/chemicals, and biological functions associated with PPIs) retrieved from public sources. By integrating this information, Dr. PIAS assesses whether a PPI is druggable as a target for small chemical ligands by using a supervised machine-learning method, support vector machine (SVM). Dr. PIAS holds not only known druggable PPIs but also all PPIs of human, mouse, rat, and human immunodeficiency virus (HIV) proteins identified to date. Conclusions: The design concept of Dr. PIAS is distinct from other published PPI databases in that it focuses on selecting the PPIs most likely to make good drug targets, rather than merely collecting PPI data.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions
    Nobuyoshi Sugaya
    Toshio Furuya
    BMC Bioinformatics, 12
  • [2] Assessing the druggability of protein-protein interactions
    Barril, X.
    DRUGS OF THE FUTURE, 2007, 32 : 12 - 13
  • [3] Dr. PIAS 2.0: an update of a database of predicted druggable protein-protein interactions
    Sugaya, Nobuyoshi
    Kanai, Satoru
    Furuya, Toshio
    DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION, 2012,
  • [4] Protein-Protein Interactions: Structures and Druggability
    Ascher, David B.
    Jubb, Harry C.
    Pires, Douglas E. V.
    Ochi, Takashi
    Higueruelo, Alicia
    Blundell, Tom L.
    MULTIFACETED ROLES OF CRYSTALLOGRAPHY IN MODERN DRUG DISCOVERY, 2015, : 141 - 163
  • [5] Druggability of constitutive protein-protein interactions
    Whitty, Adrian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [6] Assessing the druggability of protein-protein interactions by a supervised machine-learning method
    Nobuyoshi Sugaya
    Kazuyoshi Ikeda
    BMC Bioinformatics, 10
  • [7] Assessing the druggability of protein-protein interactions by a supervised machine-learning method
    Sugaya, Nobuyoshi
    Ikeda, Kazuyoshi
    BMC BIOINFORMATICS, 2009, 10 : 263
  • [8] Chemical Translational Biology: Redefining Druggability of Protein-Protein Interactions
    Cesa, Laura C.
    CHEMBIOCHEM, 2021, 22 (06) : 985 - 987
  • [9] Assessing reliability of protein-protein interactions by integrative analysis of data in model organisms
    Xiaotong Lin
    Mei Liu
    Xue-wen Chen
    BMC Bioinformatics, 10
  • [10] Assessing reliability of protein-protein interactions by integrative analysis of data in model organisms
    Lin, Xiaotong
    Liu, Mei
    Chen, Xue-wen
    BMC BIOINFORMATICS, 2009, 10